The success of Viagra initially fueled a surge for pharma, but recent changes present a murky picture for shareholders. Lower-cost versions are reducing earnings, and continued litigation add additional risk to the https://georgiaagkm202370.yomoblog.com/48486485/sildenafil-and-pharma-a-risky-investment